Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211822 · ClinicalTrials.gov registry record
Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- 57
- Enrollment target
NCT00211822: Clinical Trial study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT00211822 is a clinical trial that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211822 was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- 57 participants
- Enrollment target
Study Summary
This study will explore the brain processes associated with inhibition and reward processing in pathological gamblers and people with obsessive compulsive disorder compared to healthy controls.
Primary Outcome
a measure of behavioral response inhibition
Interventions
- PROCEDURE fMRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2004-11 |
| Est. Completion | 2010-12 |
Why NCT00211822 stopped before completion
NCT00211822 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which fMRI is the first listed.
NCT00211822 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211822 about?
NCT00211822 is a clinical study titled "Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)". This study will explore the brain processes associated with inhibition and reward processing in pathological gamblers and people with obsessive compulsive disorder compared to healthy controls.
What is the current status of trial NCT00211822?
This trial is currently terminated. The enrollment target is 57 participants. The study started on 2004-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00211822?
The interventions under investigation include: fMRI (PROCEDURE).
Who is sponsoring clinical trial NCT00211822?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia